JPH05502442A - Ｈｉｖ蛋白質のｃｔｌエピトープを含むペプチド類とその利用 - Google Patents
Ｈｉｖ蛋白質のｃｔｌエピトープを含むペプチド類とその利用Info
- Publication number
- JPH05502442A JPH05502442A JP2513793A JP51379390A JPH05502442A JP H05502442 A JPH05502442 A JP H05502442A JP 2513793 A JP2513793 A JP 2513793A JP 51379390 A JP51379390 A JP 51379390A JP H05502442 A JPH05502442 A JP H05502442A
- Authority
- JP
- Japan
- Prior art keywords
- peptide fragment
- ctl
- protein
- hiv
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 33
- 108090000623 proteins and genes Proteins 0.000 title claims description 20
- 102000004169 proteins and genes Human genes 0.000 title claims description 18
- 102000004196 processed proteins & peptides Human genes 0.000 title description 14
- 102000007079 Peptide Fragments Human genes 0.000 claims description 51
- 108010033276 Peptide Fragments Proteins 0.000 claims description 51
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 22
- 210000004027 cell Anatomy 0.000 claims description 17
- 241001465754 Metazoa Species 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 16
- 150000001413 amino acids Chemical class 0.000 claims description 13
- 230000004044 response Effects 0.000 claims description 13
- 101710192141 Protein Nef Proteins 0.000 claims description 11
- 125000000539 amino acid group Chemical group 0.000 claims description 8
- 208000015181 infectious disease Diseases 0.000 claims description 8
- 102100034353 Integrase Human genes 0.000 claims description 7
- 108010078428 env Gene Products Proteins 0.000 claims description 7
- 101710177291 Gag polyprotein Proteins 0.000 claims description 6
- 101710125418 Major capsid protein Proteins 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 238000012360 testing method Methods 0.000 claims description 6
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 claims description 5
- 241000700605 Viruses Species 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 210000004698 lymphocyte Anatomy 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims 3
- 235000018102 proteins Nutrition 0.000 description 15
- 229940024606 amino acid Drugs 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 7
- 238000003556 assay Methods 0.000 description 5
- 241000700618 Vaccinia virus Species 0.000 description 4
- -1 p-methylbenzyl group Chemical group 0.000 description 4
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 241000238557 Decapoda Species 0.000 description 3
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 229910052804 chromium Inorganic materials 0.000 description 3
- 239000011651 chromium Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241001669573 Galeorhinus galeus Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical class C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 229940033330 HIV vaccine Drugs 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 101900209501 Vaccinia virus Thymidine kinase Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000003855 acyl compounds Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000004452 microanalysis Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40959689A | 1989-09-19 | 1989-09-19 | |
| US409,596 | 1989-09-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH05502442A true JPH05502442A (ja) | 1993-04-28 |
Family
ID=23621182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2513793A Pending JPH05502442A (ja) | 1989-09-19 | 1990-09-19 | Ｈｉｖ蛋白質のｃｔｌエピトープを含むペプチド類とその利用 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0491844A4 (fr) |
| JP (1) | JPH05502442A (fr) |
| CA (1) | CA2025634A1 (fr) |
| WO (1) | WO1991004051A1 (fr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7205102B1 (en) | 1983-09-15 | 2007-04-17 | Institut Pasteur | Cloned DNA sequences related to the genomic RNA of lymphadenopathy-associated virus (LAV) and proteins encoded by said LAV genomic RNA |
| GB8423659D0 (en) | 1984-09-19 | 1984-10-24 | Pasteur Institut | Cloned dna sequences |
| US7232654B1 (en) | 1983-09-15 | 2007-06-19 | Institut Pasteur | DNA sequence of the LTR region of human immunodeficiency virus type 1 (HIV-1) |
| GB8429099D0 (en) | 1984-11-16 | 1984-12-27 | Pasteur Institut | Closed dna sequences |
| US5705612A (en) * | 1984-10-18 | 1998-01-06 | Institut Pasteur And Centre National De La Recherche Scientifique | NEF peptide encoded by human immunodefiency virus type 1 (HIV-1) |
| US7045130B1 (en) | 1984-10-18 | 2006-05-16 | Institut Pasteur | Antibodies against antigens of human immunodeficiency virus (HIV-1) |
| US5980900A (en) * | 1984-10-18 | 1999-11-09 | Institut Pasteur And Centre National De La Recherche Scientifique | Amino acid DNA sequences related to genomic RNA of human immunodeficiency virus (HIV-1) |
| US6894152B1 (en) | 1984-11-16 | 2005-05-17 | Institut Pasteur | Cloned DNA sequences related to the genomic RNA of lymphadenopathy-associated-virus (LAV) and proteins encoded by said LAV genomic RNA |
| US5128319A (en) | 1987-08-28 | 1992-07-07 | Board Of Regents, The University Of Texas System | Prophylaxis and therapy of acquired immunodeficiency syndrome |
| US6210873B1 (en) | 1987-08-28 | 2001-04-03 | Board Of Regents, The University Of Texas System | Methods and compositions for the priming of specific cytotoxic T-lymphocyte response |
| US5993819A (en) * | 1987-09-08 | 1999-11-30 | Duke University | Synthetic vaccine for protection against human immunodeficiency virus infection |
| US5221610A (en) * | 1988-05-26 | 1993-06-22 | Institut Pasteur | Diagnostic method and composition for early detection of HIV infection |
| EP0521220A1 (fr) * | 1991-06-14 | 1993-01-07 | Institut Pasteur | Actinomycétale immunogène recombinant |
| DE69230769T2 (de) * | 1991-12-02 | 2000-07-13 | Univ Texas | Zusammensetzungen zum auslösen cytotoxischer t-lymphozyten gegen viren |
| WO1993019775A1 (fr) * | 1992-03-31 | 1993-10-14 | Medimmune, Inc. | Administration de liposomes contenant des peptides ou des proteines comportant des determinants antigeniques de ctl de proteines vih |
| US5603933A (en) * | 1993-08-31 | 1997-02-18 | Board Of Regents, The University Of Texas | CD4 peptides for binding to viral envelope proteins |
| DE4405810A1 (de) | 1994-02-23 | 1995-08-24 | Behringwerke Ag | Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung |
| KR100667121B1 (ko) * | 1996-10-10 | 2007-01-12 | 프로브 인터내쇼날 | 바이러스 감염증 치료를 위한 조성물 및 방법 |
| WO2001047955A2 (fr) | 1999-12-23 | 2001-07-05 | Medical Research Council | Ameliorations des reponses immunitaires au vih |
| US6982086B2 (en) | 2000-02-04 | 2006-01-03 | Duke University | Human immunodeficiency virus immunogenic composition |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0762031B2 (ja) * | 1986-12-30 | 1995-07-05 | アメリカ合衆国 | エイズウイルスおよびエイズウイルスのタンパク質に対する細胞性免疫を誘導する合成ペプチド |
| WO1989002277A2 (fr) * | 1987-08-28 | 1989-03-23 | Board Of Regents, The University Of Texas System | Prophylaxie et therapie du syndrome immunodeficitaire acquis |
-
1990
- 1990-09-18 CA CA002025634A patent/CA2025634A1/fr not_active Abandoned
- 1990-09-19 EP EP19900914632 patent/EP0491844A4/en not_active Withdrawn
- 1990-09-19 JP JP2513793A patent/JPH05502442A/ja active Pending
- 1990-09-19 WO PCT/US1990/005343 patent/WO1991004051A1/fr not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0491844A1 (fr) | 1992-07-01 |
| EP0491844A4 (en) | 1993-02-17 |
| CA2025634A1 (fr) | 1991-03-20 |
| WO1991004051A1 (fr) | 1991-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH05502442A (ja) | Ｈｉｖ蛋白質のｃｔｌエピトープを含むペプチド類とその利用 | |
| KR100235849B1 (ko) | HIV에 대한 면역응답을 유도할 수 있는 펩티드 및 그 펩티드를 함유하는 항 AIDS 예방, 치료제(Peptides Capable of Inducing Immune Response to HIV and Anti-AIDS Agent for Preventing and Curing AIDS) | |
| US4943628A (en) | HIV peptide-inducted T cell stimulation | |
| JP2569185B2 (ja) | 抗ｈｉｖ応答を喚起する合成抗原 | |
| US5700469A (en) | HIV-1 core protein fragments | |
| Romero et al. | Immunization with synthetic peptides containing a defined malaria epitope induces a highly diverse cytotoxic T lymphocyte response. Evidence that two peptide residues are buried in the MHC molecule. | |
| JPH01501939A (ja) | 免疫抑制ペプチドおよび使用法 | |
| AU675204B2 (en) | Induction of cytolytic T-lymphocytes with cytomegalovirus polypeptides | |
| AU632683B2 (en) | Peptides stimulating cytotoxic t cells immune to hiv rt | |
| US5976541A (en) | Potent peptide for stimulation of cytotoxic T lymphocytes specific for the HIV-1 envelope | |
| WO1992005196A1 (fr) | Therapie du sida et vaccin anti-sida | |
| PT2044950E (pt) | Cassetes de imunização adn de vif atenuadas para vacinas genéticas | |
| US6210873B1 (en) | Methods and compositions for the priming of specific cytotoxic T-lymphocyte response | |
| RU2337922C9 (ru) | ИЗОЛИРОВАННЫЕ ПОЛИПЕПТИДЫ НА ОСНОВЕ НЕЙТРАЛИЗУЮЩЕГО ЭПИТОПА БЕЛКА p17 ВИРУСА ВИЧ, ИСПОЛЬЗУЕМЫЕ В КАЧЕСТВЕ ВАКЦИН, А ТАКЖЕ НЕЙТРАЛИЗУЮЩИЕ АНТИ-p17-АНТИТЕЛА, СПЕЦИФИЧЕСКИ РАСПОЗНАЮЩИЕ УКАЗАННЫЙ НЕЙТРАЛИЗУЮЩИЙ ЭПИТОП | |
| US5346989A (en) | Peptides for use in induction of T cell activation against HIV-1 | |
| US6207161B1 (en) | Induction of cytolytic T-lymphocytes with cytomegalovirus polypeptides | |
| US7521426B2 (en) | HIV-specific CTL inducing peptides and medicaments for preventing or treating AIDS comprising the peptides | |
| US7319000B1 (en) | Compositions and methods for eliciting immune or anti-infective responses | |
| EP0671947B1 (fr) | Compositions pour declencher des reactions de lymphocytes t cytotoxiques contre des virus | |
| DE69433057T2 (de) | Peptide zur verwendung bei der impfung und induktion neutralisierender antikörper gegen das menschliche immunschwäche-virus | |
| AU1906592A (en) | Peptides for use in induction of t cell activation against hiv-1 | |
| US20030203841A1 (en) | T20/DP178 and T21/DP107 are activators of human phagocyte formyl peptide receptors | |
| JPH05506039A (ja) | 治療に有用なペプチドおよびペプチド断片 | |
| Sundaram | Evaluation of T-cell and B-cell epitopes and design of multivalent vaccines against HTLV-1 diseases | |
| Syennerholm et al. | Vahlne et al. |